PL447790A1 - Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood - Google Patents

Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood

Info

Publication number
PL447790A1
PL447790A1 PL447790A PL44779024A PL447790A1 PL 447790 A1 PL447790 A1 PL 447790A1 PL 447790 A PL447790 A PL 447790A PL 44779024 A PL44779024 A PL 44779024A PL 447790 A1 PL447790 A1 PL 447790A1
Authority
PL
Poland
Prior art keywords
whole blood
risk
determining
iodine concentration
cancer
Prior art date
Application number
PL447790A
Other languages
Polish (pl)
Inventor
Adam Kiljańczyk
Milena Matuszczak
Wojciech MARCINIAK
Róża Derkacz
Klaudia Stempa
Piotr Baszuk
Marta Bryśkiewicz
Cezary Cybulski
Tadeusz Dębniak
Jacek Gronwald
Tomasz Huzarski
Marcin Lener
Anna Jakubowska
Marek Szwiec
Małgorzata Stawicka-Niełacna
Dariusz Godlewski
Artur Prusaczyk
Andrzej Jasiewicz
Tomasz Kluz
Joanna Tomiczek-Szwiec
Ewa Kilar-Kobierzycka
Monika Siołek
Rafał Wiśniowski
Renata Posmyk
Joanna Tretyn-Jarkiewicz
Rodney Scott
Steven Alexander Narod
Jan LUBIŃSKI
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL447790A priority Critical patent/PL447790A1/en
Publication of PL447790A1 publication Critical patent/PL447790A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zachorowania na raka piersi u kobiet, będących nosicielkami mutacji w genie BRCA1, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia jodu w próbce krwi pełnej osoby badanej, przy czym stężenie > 37 µg/l wskazuje na 2-krotnie zmniejszone ryzyko zachorowania na raka piersi, w stosunku do podgrupy kobiet ze stężeniem jodu < 30 µg/l w próbce krwi pełnej.The subject of the application is a method for determining the risk of developing breast cancer in women who are carriers of a mutation in the BRCA1 gene, characterized in that it includes a quantitative assessment of iodine concentration in a whole blood sample of the tested person, wherein a concentration > 37 µg/l indicates a 2-fold reduced risk of developing breast cancer, compared to the subgroup of women with iodine concentration < 30 µg/l in a whole blood sample.

PL447790A 2024-02-16 2024-02-16 Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood PL447790A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL447790A PL447790A1 (en) 2024-02-16 2024-02-16 Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447790A PL447790A1 (en) 2024-02-16 2024-02-16 Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood

Publications (1)

Publication Number Publication Date
PL447790A1 true PL447790A1 (en) 2025-08-18

Family

ID=96736202

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447790A PL447790A1 (en) 2024-02-16 2024-02-16 Method for determining the risk of cancer in women carrying a BRCA1 gene mutation depending on the iodine concentration in whole blood

Country Status (1)

Country Link
PL (1) PL447790A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL425603A1 (en) * 2018-05-17 2019-01-02 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL422787A1 (en) * 2017-09-08 2019-03-11 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women with BRCA1 mutation, depending on their age, hormonal state and concentration of arsenic, cadmium, lead, mercury, iron, zinc, copper and selenium in the blood and/or in the blood serum
PL425603A1 (en) * 2018-05-17 2019-01-02 Read-Gene Spółka Akcyjna Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VENTURI S.: "Breast 2001 Oct;10(5):379-82", „IS THERE A ROLE FOR IODINE IN BREAST DISEASES?" *
WINDER M. ET AL.: "Nutrients 2022, 14, 2209", "THE IMPACT OF IODINE CONCENTRATION DISORDERS ON HEALTH AND CANCER" *

Similar Documents

Publication Publication Date Title
Gupta et al. Iron status of toddlers, nonpregnant females, and pregnant females in the United States
Ding et al. Longitudinal trends in perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from 1999 to 2011: The Study of Women′ s Health Across the Nation
Kabat et al. Urinary estrogen metabolites and breast cancer: a case-control study.
PL440972A1 (en) Method of determining the risk of cancer in women depending on the ratio of selenium to arsenic concentrations in blood
PL425603A1 (en) Method for determining the risk of cancers in women, who are the carriers of mutation in gene BRCA1 and BRCA2 in relation to concentration of arsenic, cadmium, zinc and/or selenium in the blood
Ohba et al. Expression of nm23-H1 gene product in sarcomatous cancer cells of renal cell carcinoma: correlation with tumor stage and expression of matrix metalloproteinase-2, matrix metalloproteinase-9, sialyl Lewis X, and c-erbB-2
Kopp et al. Chemokine receptor CXCR4 based positron emission tomography imaging in systemic sclerosis-related interstitial lung disease
PL447813A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of zinc in whole blood
PL447789A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the concentration of molybdenum in whole blood
PL448873A1 (en) Method of determining the risk of cancer in women carrying mutations in the BRCA1 gene depending on the ratio of zinc to copper concentrations in whole blood
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
Drageset et al. Monitoring of disseminated tumor cells in bone marrow in high‐risk breast cancer patients treated with high‐dose chemotherapy
PL446899A1 (en) Method of determining the risk of cancer and death in women carrying BRCA1 mutations depending on blood lead concentration
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
Younesi et al. A prospective study of serum carcinoembryonic antigen in patients with newly diagnosed colorectal cancer and healthy individuals
RU2678202C1 (en) Method of predicting hematogenous metastasis in invasive carcinoma of nonspecific type of mammary gland based on determination of different populations of circulating tumor cells in blood before treatment
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL438042A1 (en) Serum chromium concentration as a prognostic marker in patients with breast cancer
PL438038A1 (en) Method of determining risk of cancer in women depending on age, history of smoking and selenium concentration in the blood
PL446712A1 (en) Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
Ameen et al. Serum ferritin levels for Iraqi patients with hashimoto's thyroiditis
Luchinin et al. Very good partial remission predicts progression-free survival in patients with multiple myeloma
Usta et al. Biological Variations of Seven Clinical Chemistry Analytes and Trolox Equivalent Antioxidant Capacity within Salivary Constituents.
PL438040A1 (en) Serum manganese concentration as a prognostic marker in patients with breast cancer
Ziai et al. An enzyme-linked double antibody immunoassay to measure murine immunoglobulins—Its application to determine the specific activity of radiolabeled monoclonal antibodies